Experimental t cell therapy targets 'Undruggable' cancer mutation in first human trial

This early-stage trial is testing a new T cell therapy called RE002 for people with advanced solid tumors that have a specific KRAS G12D mutation. Researchers will enroll 30 patients to evaluate the safety of three different dose levels and see if the treatment shows any anti-tumor effects. The therapy involves collecting a patient's own immune cells, genetically modifying them to target the cancer mutation, growing them in large numbers, and then infusing them back into the patient.